Panitumumab
Title: Panitumumab
CAS Registry Number: 339177-26-3
CAS Name: Anti-(human epidermal growth factor receptor) immunoglobulin (human monoclonal ABX-EGF heavy chain) disulfide with human monoclonal ABX-EGF light chain, dimer
Additional Names: ABX-EGF
Literature References: Fully human monoclonal antibody secreted by the E7.6.3 hybridoma; directed against human epidermal growth factor receptor (EGFr), a transmembrane cell-surface glycoprotein overexpressed in a variety of cancers. Prepn: A. Jakobovits et al., WO 9850433; eidem, US 6235883 (1998, 2001 both to Abgenix); and in vivo antitumor activity: X.-D. Yang et al., Cancer Res. 59, 1236 (1999). Clinical pharmacokinetics: E. K. Rowinsky et al., J. Clin. Oncol. 22, 3003 (2004). Review of preclinical and clinical evaluations: K. A. Foon et al., Int. J. Radiat. Oncol. Biol. Phys. 58, 984-990 (2004).
Therap-Cat: Antineoplastic.
Keywords: Antineoplastic; Monoclonal Antibodies.

Others monographs:
BromotolueneFencamineTelluric(VI) AcidCloconazole
Interleukin-102-MercaptoethanolSodium FerrocyanideGalegine
IsophytolTrilostaneMagnesium Phosphate, TribasicAndrostenedione
AzafrinLinolenic AcidEthyl PelargonateHorse-radish
©2016 DrugLead US FDA&EMEA